Immunome, Inc. (IMNM) is a biopharmaceutical company primarily engaged in discovering and developing antibody therapeutics. The company focuses on treatments for oncology and infectious diseases. Its lead oncology program is IMM-ONC-01, which targets IL-38, a tumor-derived immune checkpoint that helps tumors evade the immune system. Additionally, Immunome is developing IMM-BCP-01, an antibody cocktail aimed at treating SARS-CoV-2 infections and COVID-19. https://immunome.com/
As for the top developments of the company, three significant highlights include:
Strategic Collaboration with AbbVie: In January 2023, Immunome entered into a collaboration with AbbVie to discover up to 10 novel antibody-target pairs from three specified tumor types using Immunome’s Discovery Engine. This collaboration involves significant financial milestones and royalties for Immunome.
Formation of Advisory Board for Antibody-Drug Conjugate and T Cell Redirection: In February 2023, Immunome established an advisory board consisting of experts to prioritize the selection of novel targets for antibody drug conjugates (ADCs) and T cell redirection (TCR) modalities. This move underlines the company’s commitment to advancing its capabilities in these areas.
Participation in the World ADC London Conference: In March 2023, Immunome presented at the 13th Annual World ADC London Conference, a significant event dedicated to antibody-drug conjugate research. The company discussed how its Discovery Engine could identify novel target classes relevant for various therapeutic modalities, including ADCs.
These developments reflect Immunome’s strategic efforts in expanding its research and development in the field of oncology and infectious diseases, leveraging its proprietary technologies and engaging in significant collaborations.
